Johnson & Johnson has agreed to acquire Intra-Cellular Therapies for approximately $14.6 billion, in the largest biopharma merger-and-acquisition (M&A) deal announced in two years.

Scripps Research chemists unlock the potential of ketone and ester molecules, paving the way for greener and more efficient ...

Experiments showed that when mitochondrial protein MCJ is removed from obese mice the animals produce more heat and lose ...

EY—the professional services firm originally known as Ernst & Young—reports the dollar value of biopharma M&A deals nosedived ...